Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Ipsen
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:focusesOn |
epigenetic therapies
|
| gptkbp:foundedIn |
2007
|
| gptkbp:founder |
gptkb:Robert_Gould
gptkb:David_Allis gptkb:Yang_Shi |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Epizyme
|
| gptkbp:indication |
epithelioid sarcoma
follicular lymphoma |
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Tazverik
|
| gptkbp:stockSymbol |
gptkb:EPZM
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.epizyme.com/
|
| gptkbp:bfsParent |
gptkb:Mohr_Davidow_Ventures
gptkb:Ipsen gptkb:InterWest_Partners gptkb:Kalypsys gptkb:Beth_Seidenberg |
| gptkbp:bfsLayer |
7
|